Drug Type Small molecule drug |
Synonyms NX 019, NX-019, NX019 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Nalo Therapeutics, Inc.Startup |
Active Organization Nalo Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | US | Nalo Therapeutics, Inc.Startup | 05 Oct 2022 |
Advanced cancer | Phase 1 | KR | Nalo Therapeutics, Inc.Startup | 05 Oct 2022 |
Advanced cancer | Phase 1 | TW | Nalo Therapeutics, Inc.Startup | 05 Oct 2022 |
EGFR Mutation Lung Cancer | Phase 1 | US | Nalo Therapeutics, Inc.Startup | 05 Oct 2022 |
EGFR Mutation Lung Cancer | Phase 1 | KR | Nalo Therapeutics, Inc.Startup | 05 Oct 2022 |
EGFR Mutation Lung Cancer | Phase 1 | TW | Nalo Therapeutics, Inc.Startup | 05 Oct 2022 |